Back to top

Tale of the Tape

Zacks Equity Research

Quest Diagnostics (DGX) Looks Good: Stock Moves 6% Higher
April 21, 2017

DGX CRVS

Trades from $3

Quest Diagnostics Incorporated (DGX - Free Report) was a big mover last session, as the company saw its shares rise to 6% on the day. The upside was driven by the company’s strong results for first-quarter 2017, which topped estimates. Also, this led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up almost 6% in the past one-month time frame.

The company has seen no positive or negative estimate revision in the past 30 days. Also, its Zacks Consensus Estimate remained unchanged over the same timeframe. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Quest Diagnostics currently holds a Zacks Rank #2 (Buy).

Quest Diagnostics Incorporated Price

 

A top-ranked stock in the broader medical sector is Corvus Pharmaceuticals, Inc. (CRVS - Free Report) sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is DGX going up? Or down? Predict to see what others think: Up or Down

More Stock News: 8 Companies Verge on Apple-Like Run

Did you miss Apple's 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.

A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>





In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Quest Diagnostics Incorporated (DGX) - free report >>

Corvus Pharmaceuticals, Inc. (CRVS) - free report >>